Using autologous LN-145 cell therapy for metastatic non-small-cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial evaluates the effectiveness of LN-145, a type of autologous tumor-infiltrating lymphocyte (TIL) therapy, in patients with metastatic non-small-cell lung cancer (NSCLC). The study involves a non-myeloablative lymphodepleting preparative regimen followed by the infusion of the patient's own TILs and administration of interleukin-2 (IL-2). It is a prospective, open-label, multi-cohort, non-randomized study conducted across multiple centers to assess the safety and efficacy of this innovative treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor.
* Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations.
* For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate health authority approved targeted therapy is required.
* Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy ± bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.
* LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression
* Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.
* At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1
* Have adequate organ function
* LVEF \> 45%, NYHA Class 1
* Have adequate pulmonary function
* ECOG performance status of 0 or 1
* Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy

Exclusion Criteria:

* Patients who have EGFR, ALK or ROS1 driver mutations
* Patients who have symptomatic, untreated brain metastases.
* Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years
* Patients who have any form of primary immunodeficiency
* Patients who are on systemic steroid therapy ≥ 10 mg/day of prednisone or equivalent.
* Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
* Patients who have had another primary malignancy within the previous 3 years
* Participation in another interventional clinical study within 21 days

Where it's running

• Banner Health MD Anderson
  Gilbert, Arizona, United States Recruiting
• H Lee Moffitt Cancer Center and Research Institute
  Tampa, Florida, United States Recruiting
• Advocate Aurora Health
  Park Ridge, Illinois, United States Recruiting
• University of Louisville
  Louisville, Kentucky, United States Recruiting
• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting
• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

+21 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Iovance Biotherapeutics Study Team lungcelltherapy.com
• Email: Clinical.Inquiries@iovance.com
• Phone: 1-844-845-4682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• Safety and activity of radioligand therapy with RTX-2358 plus immune therapy in FAP-positive metastatic NSCLC

  A small, early study tests whether giving a targeted radioligand to patients with FAP-positive metastatic NSCLC, combined with a PD-1 inhibitor, is safe and shows signs of activity.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689643

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• Ubamatamab with or without REGN7075 for adults with advanced or metastatic non-small cell lung cancer

  This trial will try ubamatamab alone and with REGN7075 in adults with advanced or metastatic non-small cell lung cancer to see if they control the cancer and will try sarilumab to manage immune-related side effects.

  Recruiting at 18 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 17 other locations · NCT07154290

• MOv19-BBz CAR T cell treatment for FRa-positive lung cancer

  This trial will test whether a single intrapleural infusion of MOv19-BBz CAR T cells given after lymphodepleting chemotherapy is safe and can help control FRa-positive metastatic or recurrent non-small cell lung cancer with malignant pleural effusion.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07116057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.